Phase II Pembrolizumab PD-1 inhibitor plus Odetiglucan immune activator combination trial

Investigating safety and efficacy, Abramson Cancer Center at Penn Medicine is evaluating the combination of pembrolizumab—a PD-1 blocking monoclonal antibody—and odetiglucan, a glucan-based immune activator, in patients with liver-dominant metastatic colorectal adenocarcinoma that is MMR proficient. Enrollment targets individuals with non-MSI-H tumors, including those with KRAS/NRAS/BRAF wild-type when applicable. The trial aims to improve outcomes for this specific subset, offering first-in-combination insights.